BamSEC and AlphaSense Join Forces
Learn More

Trevi Therapeutics Inc.

NASDAQ: TRVI    
Share price (1/8/25): $4.03    
Market cap (1/8/25): $310 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 4 pages September 27, 2024
12/34/56
EX-10.2
from 10-Q 14 pages Consulting Services Agreement
12/34/56
EX-10
from 10-K 17 pages Second Amendment to Lease
12/34/56
EX-10
from 10-K 4 pages Material contract
12/34/56
EX-10.1
from 10-Q 9 pages Consulting Services Agreement
12/34/56
EX-10.1
from 8-K 11 pages Amendment No. 1 to Sales Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Material contract
12/34/56
EX-10.6
from 10-Q 4 pages Material contract
12/34/56
EX-10.5
from 10-Q 2 pages First Amendment to Exclusive License Agreement This First Amendment to Exclusive License Agreement (Hereinafter the "First
12/34/56
EX-10.7
from 10-K 1 page Non-Employee Director Compensation Program
12/34/56
EX-10.10
from 10-K 14 pages Trevi Therapeutics, Inc. Employment Agreement
12/34/56
EX-10.1
from 8-K 14 pages Trevi Therapeutics, Inc. Executive Separation Benefits and Retention Plan
12/34/56
EX-10.17
from S-1/A 18 pages Share Purchase Agreement
12/34/56
EX-10.15
from S-1/A 38 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Exclusive License Agreement by and Between Trevi Therapeutics, Inc. and Penwest Pharmaceuticals Co
12/34/56
EX-10.16
from S-1 28 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Exclusive License Agreement Between Rutgers, the State University of New Jersey and Trevi Therapeutics, Inc. Effective November 6, 2018
12/34/56
EX-10.15
from S-1 38 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Exclusive License Agreement by and Between Trevi Therapeutics, Inc. and Penwest Pharmaceuticals Co
12/34/56
EX-10.14
from S-1 6 pages First Amendment to Lease
12/34/56
EX-10.13
from S-1 42 pages Indenture of Lease 195 Church Street Trevi Therapeutics, Inc. (“Tenant”) First Niagara Bank, N.A. (“Landlord”) February 6, 2013 Indenture of Lease
12/34/56
EX-10.12
from S-1 14 pages Indemnification Agreement
12/34/56
EX-10.11
from S-1 10 pages Material contract
12/34/56